MOTS-C 10mg Review

MOTS-c occupies a genuinely unusual position in the peptide research landscape. Unlike the vast majority of bioactive peptides, which are encoded in the nuclear genome, MOTS-c is transcribed directly from mitochondrial DNA, making it a member of a small family of molecules now called mitochondrial-derived peptides (MDPs). The original 2015 discovery by Lee and colleagues at USC placed MOTS-c at the intersection of two fields that had previously had little overlap: mitochondrial biology and metabolic hormone research. 1

Seven years of subsequent investigation have produced a picture of unusual complexity. MOTS-c is not simply a metabolic regulator in the conventional sense. It acts as a retrograde mitochondria-to-nucleus signal, an exercise-responsive circulating factor, a regulator of skeletal muscle insulin sensitivity, and a modulator of systemic inflammation, all within a 16-amino-acid sequence with a molecular weight of roughly 2.2 kDa. 2 Its concentration in human plasma declines measurably with age, which has drawn substantial interest from longevity researchers and from clinical investigators studying type 2 diabetes and metabolic syndrome. 3

This review compiles the available peer-reviewed evidence as of mid-2026, structured for researchers in clinical pharmacology, biochemistry, and cell biology who need to evaluate whether MOTS-c warrants inclusion in their research programs. Every major claim is linked to a primary source. Where evidence is contested or thin, that is stated plainly.

Editor's Verdict

MOTS-c is among the better-characterized mitochondrial-derived peptides in the current research literature. Its AMPK-activating and insulin-sensitizing effects have been replicated across multiple independent rodent models, and an emerging human cohort literature connects plasma MOTS-c levels to metabolic and aging phenotypes in ways that are mechanistically coherent. 4 The 10 mg vial from Apollo Peptide Sciences represents a practical quantity for most research programs: enough to run several independent dosing arms in a murine model or to conduct multiple replicate in vitro assays with material to spare for re-analysis.

The evidence base is not yet at the level where any specific translational claim can be made about human benefit. The field is still working through basic questions around receptor identity, tissue-specific signaling differences, and dose-response linearity. Researchers entering this space should treat the compound as exploratory, with the most robust signal currently sitting in skeletal muscle metabolism and insulin signaling.

Specifications

What It Is: Chemistry, Origin, and Sequence

Mitochondrial DNA as a Peptide-Coding Locus

The conventional view of mitochondrial DNA (mtDNA) held for decades that its 16,569 base pairs encoded only 13 proteins (all subunits of the oxidative phosphorylation complexes), 22 transfer RNAs, and 2 ribosomal RNAs. MOTS-c overturned part of that picture. The peptide is encoded within the 12S ribosomal RNA gene of mtDNA, a region previously considered non-protein-coding. Lee et al. (2015) identified an open reading frame within this gene that, when translated, produces a 16-amino-acid peptide. 1 The finding established MOTS-c as the founding member of what is now recognized as a broader class of short open reading frame-encoded peptides arising from mitochondrial non-coding regions.

This origin is not a trivial biochemical detail. Because MOTS-c is encoded in mitochondria but acts on nuclear gene expression, it represents a mitochondria-to-nucleus signaling axis, sometimes termed retrograde signaling. The mitochondrial genome uses a slightly different codon table than the nuclear genome (the standard AGA codon for arginine reads as "stop" in mitochondria), so the sequence was not predicted by early bioinformatic scans for peptide-coding open reading frames. The discovery required direct experimental peptide identification followed by back-translation. 5

Primary Sequence and Structural Features

The canonical human MOTS-c sequence is Tyr-Arg-Trp-Leu-His-Pro-Glu-Trp-Arg-Trp-Glu-Pro-Cys-Ser-Phe-Glu, usually written in single-letter code as YRWLHPEWRWEPCSFE. Several features of this sequence are biologically noteworthy. The two central tryptophan residues (positions 4 and 8, and a third at position 10) contribute to its amphipathic character and are thought to be important for membrane interaction. A cysteine residue at position 13 can participate in disulfide bond formation, which has implications for oxidative stability and folding behavior in biological fluids. 6

The peptide has a calculated molecular weight of approximately 2,174 Da and an isoelectric point around 8.0, making it slightly basic at physiological pH. Its small size places it below the threshold of most standard chromatographic separation methods used for larger peptides, which creates both analytical challenges and opportunities: MOTS-c can be quantified by LC-MS/MS with high sensitivity in plasma and tissue extracts at picomolar concentrations. 7

Evolutionary Conservation and Isoforms

Human MOTS-c shows partial sequence conservation across mammals, though the degree varies by species. A naturally occurring variant, MOTS-c K14Q, has been identified in human cohorts and is associated with reduced metabolic protection in some genetic association studies, providing indirect genetic evidence that the canonical sequence has functional specificity. 8 A separate exercise-induced circulating form has been reported that may differ in modification state from the basal peptide, though the biochemical details of any post-translational modifications remain an open research question as of 2026.

Mechanism of Action

AMPK Activation and Metabolic Reprogramming

The primary mechanistic pathway identified for MOTS-c involves activation of AMP-activated protein kinase (AMPK), the master metabolic sensor that responds to reductions in cellular energy charge (low ATP/AMP ratio). Lee et al. (2015) demonstrated that MOTS-c treatment of C2C12 myotubes increased AMPK phosphorylation at Thr172 in a dose-dependent fashion, and that this effect was attenuated by pharmacological AMPK inhibition. 1 Downstream consequences of AMPK activation in that experimental system included increased fatty acid oxidation, suppression of de novo lipogenesis, and enhanced glucose uptake through GLUT4 translocation.

The mechanistic chain is not fully resolved. MOTS-c does not appear to directly bind AMPK. The current working model, developed across several subsequent papers, proposes that MOTS-c enters cells (possibly via an uncharacterized cell-surface receptor or through endocytosis) and then interferes with folate cycle intermediates in a way that raises the cellular AMP/ATP ratio, thereby activating AMPK indirectly. 9 Specifically, MOTS-c has been shown to inhibit the AICAR transformylase step in the de novo purine synthesis pathway, causing AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) to accumulate. AICAR is itself an endogenous AMPK activator, providing a biochemically coherent link between the mitochondria-derived signal and nuclear metabolic reprogramming.

This folate cycle interference model is elegant but still requires additional experimental validation in primary human cell types. Most of the data come from murine myotubes and hepatocyte cell lines, and it remains to be established whether the same pathway operates in human adipose tissue, brain, or immune cells at the concentrations of MOTS-c that are physiologically achievable.

Nuclear Translocation and Transcriptional Effects

One of the more striking findings in the MOTS-c literature is evidence of nuclear localization. Bhatt et al. and subsequent groups used confocal imaging with fluorescently tagged MOTS-c to demonstrate that a fraction of exogenously applied peptide reaches the nucleus of skeletal muscle cells, where it appears to interact with chromatin-associated proteins. 10 The transcriptional consequences include upregulation of NRF2 target genes (heme oxygenase-1, NQO1, and several other antioxidant response element-driven genes) and suppression of NF-kB-driven inflammatory gene expression.

The NRF2 connection is particularly relevant to longevity research. NRF2 is one of the central regulators of the cellular stress response, and its activity declines with aging in multiple tissues. MOTS-c-mediated NRF2 activation could represent a mechanism by which mitochondrial signaling communicates cellular energy status to the antioxidant defense machinery, creating a feedback loop that protects mitochondria from oxidative damage during periods of metabolic stress. 11

Whether nuclear localization is required for all of MOTS-c's biological effects, or whether membrane-proximal signaling is sufficient for the metabolic phenotype, has not been resolved. Researchers designing in vitro experiments should consider using cell-impermeable variants or compartment-restricted delivery systems to dissect these contributions.

MAPK Signaling and Inflammation

Several studies have reported that MOTS-c modulates mitogen-activated protein kinase (MAPK) pathways, specifically ERK1/2 and p38 MAPK, in the context of inflammation and immune cell biology. Reynolds et al. (2021) showed that MOTS-c administration in a murine sepsis model suppressed LPS-induced TNF-alpha and IL-6 production in macrophages through a pathway that required both p38 MAPK inhibition and AMPK activation. 12 The anti-inflammatory effect was dose-dependent across a range of 0.1 to 10 mg/kg in that in vivo model.

In cancer biology research, MOTS-c has been reported to activate ERK-dependent apoptosis in certain tumor cell lines, an effect that appears to be cell-type specific and potentially contradictory to its cytoprotective role in normal tissues. This context-specificity is a recurring theme in the literature and complicates the extrapolation of any single mechanistic narrative to all tissue types.

Tissue Distribution and Expression Patterns

Endogenous MOTS-c is detectable in human plasma, skeletal muscle, adipose tissue, liver, brain, and cerebrospinal fluid, consistent with systemic circulation from a mitochondria-rich source. Skeletal muscle appears to be a primary site of both production and action, and plasma levels rise acutely during aerobic exercise, suggesting that exercise-induced MOTS-c release contributes to the beneficial metabolic effects of physical activity. 13

A 2021 study by Kim et al. reported measurable MOTS-c in the hypothalamus and hippocampus of rodents, with behavioral and electrophysiological evidence of central nervous system activity. This has driven interest in the peptide's potential as a neuroprotective agent, though the CNS literature is substantially thinner than the metabolic literature and should be treated with more caution. 14

Age-dependent decline in plasma MOTS-c has been documented in both cross-sectional human cohorts and longitudinal studies. One cross-sectional analysis of 384 Japanese subjects found plasma MOTS-c to be significantly lower in subjects over 60 compared to those under 40, with the decline correlating inversely with fasting insulin and triglyceride levels. 3 Whether this decline is causally related to age-associated metabolic deterioration or is a parallel biomarker remains to be established.

What the Research Says

Study 1: Lee et al. (2015) - The Discovery Paper

The founding study by Lee, Dho, and colleagues at the University of Southern California identified MOTS-c and characterized its primary metabolic actions in cell culture and murine models. 1 The study used C2C12 murine myotubes as the primary in vitro model, treating cells with synthetic MOTS-c at concentrations ranging from 0.1 to 10 micromolar. The key endpoint was glucose uptake, measured via 2-NBDG fluorescence assay. MOTS-c treatment increased glucose uptake by approximately 1.8-fold at 1 micromolar compared to vehicle, an effect comparable in magnitude to maximal insulin stimulation but mechanistically distinct in that it was not blocked by phosphatidylinositol 3-kinase inhibition.

The in vivo component used C57BL/6 mice fed a high-fat diet for 10 weeks as a model of diet-induced obesity and insulin resistance. Animals received intraperitoneal injections of MOTS-c at 5 mg/kg or vehicle for 2 weeks. MOTS-c-treated animals showed significantly improved insulin tolerance (glucose clearance approximately 30% faster in insulin tolerance tests) and reduced fasting blood glucose, with no change in body weight over the 2-week treatment period. The lack of body weight change despite improved insulin sensitivity was notable, and the authors proposed that MOTS-c primarily improves glucose partitioning rather than reducing caloric intake.

Limitations of this study include the short treatment duration, the use of a single intraperitoneal route, and the absence of pharmacokinetic data. The discovery of the folate cycle mechanism was preliminary in this paper and has been substantially developed in subsequent work. Nevertheless, the core finding that a mitochondria-encoded peptide could systemically improve insulin sensitivity through an AMPK-dependent mechanism has been independently replicated and stands as one of the more robust observations in the field.

Study 2: Fuku et al. (2015) - Longevity Association in Humans

Almost simultaneously with the Lee discovery paper, Fuku and colleagues published a human genetic study examining MOTS-c variants in centenarian cohorts. 5 The study analyzed the frequency of the mt-rRNA-encoded MOTS-c sequence in 289 Japanese centenarians (age 100 or older) compared to 356 younger control subjects. A coding variant, K14Q (lysine to glutamine at position 14), was found at significantly lower frequency in centenarians (odds ratio approximately 0.41, p=0.003), suggesting that the wild-type MOTS-c sequence confers a survival advantage.

This genetic association study design has inherent limitations, including potential population stratification and the inability to determine whether the K14Q variant affects peptide secretion, stability, receptor binding, or all three. The sample size, while adequate for a genetic association study, is modest by genome-wide association standards. Regardless, the finding provided an independent line of evidence, from human population genetics rather than cell culture, that MOTS-c activity has relevance to the biology of healthy aging.

The same group followed up with in vitro characterization showing that K14Q peptide has reduced ability to translocate to the nucleus and reduced capacity to activate NRF2 target genes compared to wild-type MOTS-c. This mechanistic follow-up substantially strengthened the inference from the population genetics, though the functional experiments were again performed in transformed cell lines rather than primary human cells.

Study 3: Reynolds et al. (2021) - Exercise and Aging Phenotypes

Reynolds and colleagues at USC (a continuation of the Lee laboratory program) published a 2021 paper examining whether exogenous MOTS-c administration could recapitulate some effects of exercise in aged mice. 15 This study is notable because it moved beyond metabolic endpoints to examine physical performance. Male and female C57BL/6 mice aged 12 months were randomized to receive daily MOTS-c (5 mg/kg, subcutaneous) or vehicle for 4 weeks, with one arm also receiving a voluntary running wheel (exercise group).

The key findings were that MOTS-c administration significantly improved grip strength, rotarod performance, and voluntary running distance compared to sedentary vehicle-treated controls, with effect sizes roughly 60-70% as large as those seen in the exercise group. Transcriptomic analysis of skeletal muscle from MOTS-c-treated animals showed upregulation of gene sets associated with mitochondrial biogenesis, fiber type switching toward oxidative phenotypes, and antioxidant defense. Circulating inflammatory markers (IL-6, TNF-alpha) were reduced in MOTS-c-treated animals relative to sedentary controls.

A critical limitation of this study is that it was conducted in young-to-middle-aged rather than old mice, which may not fully capture the biology of age-associated decline. The 4-week treatment duration also precludes conclusions about chronic administration safety or durability of effects. The exercise mimetic framing, while scientifically interesting, requires careful interpretation because the downstream transcriptomic signature of MOTS-c overlaps with but is not identical to that of exercise.

Study 4: Zhai et al. (2023) - Cognitive and Neuroprotective Effects

Zhai and colleagues published a 2023 study examining MOTS-c effects in a murine model of Alzheimer's disease pathology. 16 They used APP/PS1 transgenic mice and administered MOTS-c at 5 mg/kg intraperitoneally three times per week for 8 weeks. Cognitive outcomes were assessed via Morris water maze and novel object recognition tests. MOTS-c-treated APP/PS1 mice showed significantly improved spatial learning (escape latency reduced by approximately 35% compared to vehicle-treated transgenic controls) and improved object recognition memory (discrimination index 0.42 vs. 0.28 in controls, p<0.01).

Mechanistically, the paper demonstrated that MOTS-c reduced amyloid-beta plaque burden in the hippocampus by approximately 40% (as assessed by thioflavin-S staining), reduced activated microglia counts, and increased dendritic spine density in CA1 pyramidal neurons. Protein-level analysis showed increased hippocampal BDNF, phospho-CREB, and reduced NF-kB p65 nuclear translocation, consistent with a combined neurotrophic and anti-inflammatory mechanism.

This study represents one of the more comprehensive explorations of MOTS-c in a CNS disease model, but several caveats apply. APP/PS1 mice are a disease model rather than normal aging, and the relationship between amyloid pathology in transgenic overexpression models and human Alzheimer's disease is complex and contested. The route (intraperitoneal) and dose used are not pharmacokinetically characterized for CNS penetration in this paper. Researchers considering MOTS-c for neuroprotection studies should design experiments that include pharmacokinetic measurements of cerebrospinal fluid levels.

Study 5: Ming et al. (2022) - Inflammation and Sepsis

Ming, Lee, and colleagues published a 2022 study examining MOTS-c's role in modulating systemic inflammation in a cecal ligation and puncture (CLP) model of sepsis. 17 This model, which is considered more clinically relevant than LPS injection because it produces polymicrobial peritonitis with secondary bacteremia, is one of the most stringent tests of an anti-inflammatory intervention. MOTS-c was administered at 2 mg/kg intravenously at 6 hours after CLP in C57BL/6 mice.

Seven-day survival was 55% in MOTS-c-treated animals versus 25% in vehicle controls (p=0.03). Treated animals had lower circulating IL-6 and IL-1beta at 24 hours, reduced organ damage scores in kidney and liver sections at 48 hours, and improved bacterial clearance in peritoneal lavage fluid at 12 hours. The bacterial clearance finding suggested that the beneficial effect was not simply immunosuppressive but involved a qualitative improvement in innate immune function, specifically macrophage phagocytic capacity.

The mechanistic work in this paper proposed that MOTS-c activates macrophage AMPK, which in turn increases mitochondrial biogenesis and oxidative phosphorylation in macrophages, supporting the metabolic demands of phagocytosis while simultaneously reducing inflammatory cytokine secretion. This dual effect (pro-phagocytic and anti-inflammatory) is conceptually coherent with the known metabolic effects of AMPK in macrophages but requires direct confirmation in human macrophage systems before translational conclusions can be drawn.

Open Research Questions

Several important mechanistic questions remain unresolved as of mid-2026. First, the identity of any extracellular receptor for MOTS-c has not been established. While the folate cycle interference model provides a plausible intracellular mechanism, a surface receptor would need to exist to explain the rapid (minutes-scale) transcriptional responses seen in some cell-based studies, unless internalization is faster than typically assumed.

Second, the relationship between exercise-induced MOTS-c release and the beneficial effects of chronic exercise training has not been quantitatively established. If exercise elevates plasma MOTS-c by 2-fold acutely, and if this elevation contributes to the known metabolic benefits of exercise, what is the relative contribution compared to other exercise-responsive myokines such as irisin or IL-6?

Third, sexual dimorphism in MOTS-c biology is suggested by several rodent studies where female animals responded differently to exogenous MOTS-c than males, but no systematic pharmacological analysis of sex differences has been published. This is an important gap given the known sex differences in metabolic and aging phenotypes that MOTS-c is proposed to regulate.

Pharmacokinetics

The pharmacokinetic profile of MOTS-c is consistent with what is expected for a small peptide of approximately 2 kDa. The estimated plasma half-life of 20-40 minutes in murine models reflects rapid renal filtration (the peptide falls below the ~50 kDa glomerular cutoff by a large margin) combined with tissue uptake. 1 This short half-life has driven some researchers to explore subcutaneous administration, which produces a more sustained absorption profile from the injection site depot and may be more relevant for chronic treatment protocols.

CNS penetration represents a particularly complex pharmacokinetic question for MOTS-c. The blood-brain barrier presents a size and polarity-based filter that would not be expected to freely pass a 2 kDa peptide without active transport. Yet several groups have reported measurable MOTS-c in cerebrospinal fluid following peripheral administration, and the behavioral effects in APP/PS1 mice following intraperitoneal dosing suggest either CNS penetration or a periphery-to-brain signaling relay involving peripheral nerve afferents or circulating immune mediators. 14

The endogenous plasma concentration in healthy adult humans is in the low nanomolar range (approximately 0.5-2 nM), with substantial inter-individual variability that correlates with fitness level, age, and metabolic health status. 3 Pharmacological doses used in murine research (typically 5 mg/kg) would, if directly scaled to humans by body weight, produce circulating levels orders of magnitude above this physiological range, which underscores the importance of not extrapolating animal dosing to any human context.

Purity and Verification

What to Expect on a Certificate of Analysis

A credible Certificate of Analysis (CoA) for a research-grade MOTS-c vial should contain at minimum four data elements. First, HPLC purity expressed as area percentage, with a chromatogram or at least a reported retention time and purity value. For research applications requiring reproducible dose-response characterization, purity below 95% is generally considered insufficient; the Apollo Peptide Sciences specification is greater than 98% by HPLC. Second, mass spectrometry confirmation, typically electrospray ionization (ESI-MS) or MALDI-ToF, showing the observed molecular ion consistent with the theoretical mass of MOTS-c. For the canonical 16-residue sequence, the expected monoisotopic mass is approximately 2,173.5 Da; a deviation of more than 2 Da on a correctly calibrated instrument should prompt investigation. 6

Third, the CoA should specify the peptide sequence or lot number traceable to a sequence record, confirming that the material is the correct isomer and not a scrambled or truncated version. Fourth, for MOTS-c specifically, the cysteine at position 13 raises the question of disulfide bond status. The CoA or accompanying technical note should indicate whether the material is provided in reduced (free thiol) form or as a dimer. Research applications generally require the reduced monomer, and storage in a reducing environment (or reconstitution with a small amount of dithiothreitol in some protocols) may be warranted if oxidation is suspected.

Independent Verification Approaches

Researchers who require independent verification beyond the vendor CoA have several practical options. LC-MS/MS with a peptide sequencing workflow can provide sequence confirmation and quantitative purity assessment in approximately 48 hours at most core facilities. The MOTS-c sequence, with its three tryptophan residues, provides strong UV absorbance at 280 nm, which is useful for independent concentration verification by Beer-Lambert absorbance (using the calculated molar extinction coefficient of approximately 17,990 M-1 cm-1).

For functional verification, AMPK phosphorylation assay in C2C12 myotubes is a well-validated bioactivity test. A credible preparation of MOTS-c at 1-5 micromolar should produce a reproducible increase in phospho-Thr172 AMPK within 30-60 minutes of treatment, detectable by standard immunoblot with commercially available antibodies. If the preparation fails this bioactivity test despite showing correct mass, it may indicate structural issues with the cysteine (e.g., oxidized or incorrectly folded) that mass spec alone would not detect.

Researchers seeking guidance on interpreting CoA documents and selecting suppliers with consistent quality controls should consult the peptide supplier evaluation guide and our CoA reading guide.

Dosage and Reconstitution

Reconstitution Protocol

Reconstituting lyophilized MOTS-c requires care because the peptide contains a cysteine residue susceptible to oxidative dimerization and three tryptophan residues that can degrade under UV exposure. The recommended primary solvent is sterile water (molecular biology grade or HPLC grade), added slowly to the side of the vial rather than directly onto the lyophilized powder to avoid foaming. Gentle swirling rather than vortexing is advised. If the peptide does not fully dissolve in water alone, a small volume of 0.1 M acetic acid can be added to the initial dissolution, followed by dilution to working concentration with sterile saline or PBS. 1

For detailed, step-by-step reconstitution technique including volume calculations, sterile filtration, and aliquoting, see the peptide reconstitution guide.

A worked example for a 10 mg vial: if the research protocol requires a 1 mg/mL stock solution, add 10 mL of sterile water to the vial. If the protocol requires 0.5 mg/mL, add 20 mL. A 10 mg vial is large enough that most researchers will want to aliquot the reconstituted solution into smaller volumes (0.5-1 mL per cryotube) immediately after reconstitution to avoid repeated freeze-thaw cycles, which accelerate tryptophan oxidation and cysteine dimerization.

Literature-Reported Research Doses

Murine metabolic models. The most frequently cited in vivo dose in diet-induced obesity and insulin resistance models is 5 mg/kg administered intraperitoneally once daily. In the Lee et al. (2015) study, this dose produced measurable improvements in insulin tolerance within 2 weeks. 1 In the Reynolds et al. (2021) exercise phenotype study, the same dose by subcutaneous route over 4 weeks produced the muscle and performance endpoints described above. 15

Murine sepsis models. Ming et al. (2022) used 2 mg/kg intravenous administration at a single post-challenge timepoint. 17 This lower dose in the acute inflammatory model is consistent with a shorter required duration of action and a more direct delivery route.

In vitro cell culture. Concentration ranges from 0.1 to 10 micromolar are used most commonly in myotube and hepatocyte systems, with 1 micromolar being a common reference point for AMPK activation assays. Higher concentrations (10 micromolar) are used when studying anti-inflammatory gene expression in macrophage cell lines.

Worked dosing calculation example 1: A researcher plans to dose 25 mice at 5 mg/kg based on an average body weight of 25 g. Each animal receives 0.125 mg per injection (5 mg/kg x 0.025 kg). Total peptide consumption per injection session is 3.125 mg. A 10 mg vial supports approximately three full injection sessions with material remaining for additional measurements, making the 10 mg vial appropriate for a 2-week once-daily protocol with this group size.

Worked dosing calculation example 2: A researcher needs to treat cells in a 24-well plate with 1 micromolar MOTS-c. The molecular weight of MOTS-c is 2,174 Da. A 1 mM stock solution requires 2.174 mg/mL. From a 10 mg vial reconstituted to 4.588 mL with sterile water, the researcher obtains a 1 mM stock. Diluting 1 microliter of this stock into 999 microliters of cell culture medium gives a 1 micromolar working solution. The 10 mg vial provides enough material for tens of thousands of such 24-well experiments, which means in vitro researchers should plan aliquot sizes accordingly to avoid wasting material to freeze-thaw degradation.

Worked dosing calculation example 3: A researcher working with aged rats (average 450 g) wants to replicate the 5 mg/kg protocol. Each animal requires 2.25 mg per injection. A 10 mg vial provides material for 4.4 animal-injections at this dose, meaning two or three vials would be needed for a multi-week study in this species.

For general guidance on dose calculations, dilution series, and unit conversions, see the peptide dosage calculation guide.

Side Effects and Safety

Observed Adverse Effects in Animal Research

Across the published murine studies summarized in this review, MOTS-c at doses of 2-5 mg/kg administered daily for up to 4 weeks did not produce overt toxicity, organ damage (assessed histologically), or mortality attributable to the peptide itself. Body weight, food intake, and standard clinical chemistry panels (ALT, AST, creatinine, BUN) were reported as normal in the Lee et al. and Reynolds et al. studies. 115

Injection site reactions have not been specifically characterized in the published literature, but are expected to be minimal given the small peptide size and neutral formulation. Hypoglycemia is a theoretical risk in any agent that improves insulin sensitivity and increases glucose uptake in insulin-independent fashion. In the Lee et al. study, fasting glucose was reduced in treated animals but did not fall into hypoglycemic ranges. Researchers using MOTS-c in metabolic models should monitor blood glucose, particularly in animals that are already on calorie restriction or receiving other hypoglycemic agents.

Immunogenicity Considerations

At 16 amino acids, MOTS-c is at the lower boundary of peptide lengths that can reliably generate antibody responses. A T-cell-dependent antibody response typically requires peptides of 15 amino acids or longer presented in the context of carrier proteins, but free MOTS-c is unlikely to be significantly immunogenic without adjuvant. No studies have specifically examined whether chronic MOTS-c administration in rodents produces neutralizing antibodies, which would be an important consideration for studies lasting more than 4-8 weeks. Researchers planning chronic administration protocols should consider including antibody titer measurements as a study endpoint.

Theoretical Risks Based on Mechanism

Because MOTS-c inhibits steps in the folate cycle and purine synthesis pathway, theoretical concerns exist around potential interference with nucleotide biosynthesis in rapidly proliferating cells. This could be relevant in the context of immune system function, gut epithelial renewal, or hematopoiesis. No published study has specifically examined MOTS-c effects on cell proliferation indices in these tissues in vivo, representing a gap in the safety literature that should be addressed before any future clinical translation.

The cysteine residue also raises the question of off-target disulfide chemistry in the redox-active extracellular environment. While the peptide is too small to engage in most classical protein-protein disulfide interactions with folded proteins, the possibility of covalent modification of reactive cysteines in surface receptors or transporters has not been systematically investigated.

How It Compares

MOTS-c Versus Humanin

Humanin is the closest comparator to MOTS-c, as both are mitochondrial-derived peptides with documented metabolic and cytoprotective functions. Humanin is larger (21 amino acids, approximately 2.8 kDa) and signals through a well-characterized receptor complex consisting of gp130 and CNTFR-alpha with IL-27Ra, which is distinct from any proposed MOTS-c receptor. 18 Humanin's primary described functions include neuroprotection (particularly against Alzheimer's-like neurodegeneration), cardioprotetion, and anti-apoptotic effects in multiple tissues. MOTS-c's primary described functions are more metabolic in character, centered on insulin sensitivity and AMPK activation.

From a research prioritization standpoint, the two peptides are not interchangeable. Researchers focused on metabolic insulin sensitivity and exercise biology will find MOTS-c better aligned with their target biology. Researchers focused on neurodegeneration or cardiomyocyte protection may find the humanin literature more directly relevant. Both peptides have active investigator communities, which is reflected in the volume of publications from 2020-2026.

MOTS-c Versus SS-31 (Elamipretide)

SS-31 represents a more clinically advanced mitochondria-targeting peptide strategy. Unlike MOTS-c, SS-31 is a synthetic, non-natural peptide designed to concentrate in the inner mitochondrial membrane by interacting with cardiolipin. It has completed Phase II trials for heart failure and Barth syndrome, giving it substantially more rigorous human safety and efficacy data than MOTS-c. 11 However, SS-31's mechanism is fundamentally physical (membrane stabilization) rather than signaling-based, which means it does not address the metabolic reprogramming or transcriptional regulation that MOTS-c targets. For researchers specifically interested in the AMPK-NRF2 axis or the exercise mimetic concept, SS-31 is not a direct comparator.

Position in the Longevity Peptide Landscape

Relative to Epitalon (a synthetic tetrapeptide based on epithalamin, the proposed active component of the pineal gland extract used in Soviet-era longevity research), MOTS-c has a substantially better-characterized mechanistic basis and more recent, methodologically rigorous supporting studies. Epitalon's evidence base relies heavily on Russian-language literature with limited international replication and unclear purification standards. MOTS-c, by contrast, was described in Cell Metabolism, characterized by multiple independent groups, and has a coherent mechanistic explanation grounded in mainstream mitochondrial biology. This does not mean MOTS-c's clinical relevance is established, but it does mean the research foundation is stronger.

Where to Buy

Apollo Peptide Sciences is the vendor for the MOTS-c 10mg vial reviewed in this article. Researchers can review the full product listing, including lot-specific CoA data, at the MOTS-c 10mg product page. As with any research peptide supplier, prospective buyers should review the supplier's testing standards, CoA availability, and return policy before placing an order.

For a broader evaluation of research peptide vendors, including criteria for assessing HPLC purity claims, mass spec confirmation standards, and cold-chain shipping practices, consult the peptide supplier guide. Price alone is a poor proxy for quality in the research peptide market; the correlation between price and actual purity has been shown to be weak in third-party testing surveys.

Researchers working with multiple compounds in the longevity or metabolic category may also find the following product reviews relevant to their program planning:

• See the BPC-157 review for a contrasting regenerative peptide with a different mechanistic profile.
• The humanin review provides direct comparison material for the MDP class.

When evaluating any vendor for a peptide of this complexity, requesting a lot-specific CoA with both HPLC and MS data before purchase is a standard due-diligence step. A vendor that cannot supply this documentation on request should not be used for quantitative research applications.

FAQ